



MAIL DATE CANCELLED



Attachment
09/595682
5
Sheet 01 of 04

Form PTO-1449 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.
SJ-0005

Serial No. **09/595,682**

Applicant
DANKS ET AL.

JAN 10 2001

Filing Date
JUNE 16, 2000

Group
1643

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	AA	Bello-Fernandez, C., et al., "The ornithine decarboxylase gene is a transcriptional target of c-Myc", 1993 Proc. Natl. Acad. Sci. USA 90:7804-7808
	AB	Brodeur, G.M., et al., "Biology and Genetics of Human Neuroblastomas", 1997 J. Ped. Hematol. Oncol. 19:93-101
	AC	Dachs et al., "Targeting Gene Therapy to Cancer: A Review", 1997 Oncol. Res. 9:313-325
	AD	Davis et al., "Current progress in the gene therapy of cancer", 1996 Current Opinion in Oncology 8:499-508
	AE	Field, et al., "Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma", 1989 Oncogene 4:1463-1468
	AF	Haaz, M.C., et al., "Metabolism of Irinotecan (CPT-11) by Human Hepatic Microsomes: Participation of Cytochrome P-450 3A and Drug Interactions ¹ ", 1998 Cancer Res. 58:468-472
	AG	Hanania et al., "Recent Advances in the Application of Gene Therapy to Human Disease", 1995 Am. Jour. Med. 99:537-552
	AH	Houghton, P.J., et al., "Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors", 1995 36:393-403
	AI	Houghton, P.J., et al., "Therapeutic Efficacy of the Topoisomerase I Inhibitor 7-Ethyl-10-(4-([1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against Human Tumor Xenografts: Lack of Cross-Resistance in Vivo in Tumors with Acquired Resistance to the Topoisomerase I Inhibitor 9-Dimethylaminomethyl-10-hydroxycamptothecin ¹ ", 1993 53:2823-2829

EXAMINER

DATE CONSIDERED

11/17/02

MAIL DATE CANCELLED
 OIPE JC19
 JAN 08 2000
 PATENT & TRADEMARK OFFICE

OIPE JC19
 JAN 08 2001
 PATENT & TRADEMARK OFFICE

Sheet 02 of 04

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. SJ-0005	Serial No. 09/595,682
	Applicant DANKS ET AL.	
	Filing Date JUNE 16, 2000	Group 1643

RECEIVED
 JAN 10 2001
 TECH CENTER 1600/2900


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ca	AJ	Hsiang, Y.-H. et al., "Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin", 1989 <i>Cancer Res.</i> 49:5077-5082
	AK	Humerickhouse et al., "Characterization of CPT-11 Hydrolysis by Human Liver Carboxylesterase Isoforms hCE-1 and hCE-2 ¹ ", 2000 <i>Cancer Res.</i> 60:1189-1192
	AL	Johnson et al., "Current therapy for cutaneous melanoma", 1995 <i>J. Am. Acad. Derm.</i> 32(5):689-707
	AM	Kaneda, N. et al., "Metabolism and Pharmacokinetics of the Camptothecin Analogue CPT-11 in the Mouse", 1990 <i>Cancer Res.</i> 50:1715-1720
	AN	Kawasaki, H. et al., "Specific Regulation of Gene Expression by Antisense Nucleic Acids: A Summary of Methodologies and Associated Problems", 1996 <i>Artif. Organs</i> 20(8):836-848
	AO	Kawato, Y. et al., "Intracellular Roles of SN-38, a Metabolite of the Camptothecin Derivative CPT-11, in the Antitumor Effect of CPT-11", 1991 <i>Cancer Res.</i> 51:4187-4191
	AP	Korza, G. and J. Ozols, "Complete Covalent Structure of 60-kDa Esterase Isolated from 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced Rabbit Liver Microsomes" 1988 <i>J. Biol. Chem.</i> 263:3486-3495
	AQ	Kumagai, T. et al., "Eradication of Myc-overexpressing Small Cell Lung Cancer Cells Transfected with Herpes Simplex Virus Thymidine Kinase Gene Containing Myc-Max Response Elements ¹ ", 1996 <i>Cancer Res.</i> 56(2):354-358
✓	AR	Leinweber, F.J., "Possible Physiological Roles of Carboxylic Ester Hydrolases", 1987 <i>Drug Metab. Rev.</i> 18:379-439

EXAMINER

DATE CONSIDERED

1/17/02



Sheet 03 of 04



Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. SJ-0005	Serial No. 09/595,982
	Applicant DANKS ET AL.	
	Filing Date JUNE 16, 2000	Group 1643 TECH CENTER 1600/2900

RECEIVED**JAN 10 2001****OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

CA	AS	Lutz et al., "Conditional expression of N-myc in human neuroblastoma cells increases expression of α -prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells", 1996 <i>Oncogene</i> 13:803-812
	AT	Matthay, K.E., "Neuroblastoma: Biology and Therapy", 1997 <i>Oncology</i> 11:1857-1875
	AU	Matthay, K.E., et al., "Patterns of Relapse After Autologous Purged Bone Marrow Transplantation for Neuroblastoma: A Childrens Cancer Group Pilot Study", 1993 <i>J. Clin. Oncol.</i> 11:2226-2233
	AV	Nagai, M.A., et al., "Association of Genetic Alterations of c-myc, c-fos, and c-Ha-ras Proto-Oncogenes in Colorectal Tumors", 1992 <i>Dis. Colon Rectum</i> 35:444-451
	AW	Orian, J.M., et al., "Overexpression of multiple oncogenes related to histological grade of astrocytic glioma", 1992 <i>Br. J. Cancer</i> 66:106-112
	AX	Raschella, G., et al., "Lack of Correlation between N-myc and MAX Expression in Neuroblastoma Tumors and in Cell Lines: Implication for N-myc-MAX Complex Formation ¹ ", 1994 <i>Cancer Res.</i> 54:2251-2255
	AY	Rill, D.R., et al., "Direct Demonstration That Autologous Bone Marrow Transplantation for Solid Tumors Can Return a Multiplicity of Tumorigenic Cells", 1994 <i>Blood</i> 84:380-383
	AZ	Riou, G., et al., "C-myc PROTO-ONCOGENE EXPRESSION AND PROGNOSIS IN EARLY CARCINOMA OF THE UTERINE CERVIX", 1987 <i>Lancet</i> 2:761-763
✓	BA	Rivory, et al., "Identification and Properties of a Major Plasma Metabolite of Irinotecan (CPT-11) Isolated from the Plasma of Patients ¹ ", 1996 <i>Cancer Res.</i> 56:3689-3694

EXAMINER**DATE CONSIDERED**

1/17/02



Sheet 04 of 04

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. SJ-0005	Serial No. 09/595,688
	Applicant DANKS ET AL.	
	Filing Date JUNE 16, 2000	Group 1643

RECEIVED**JAN 10 2001****TECH CENTER 1600/2900****OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

✓	BB	Rivory, L.P., et al., "Pharmacokinetic Interrelationships of Irinotecan (CPT-11) and Its Three Major Plasma Metabolites in Patients Enrolled in Phase I/II Trials", 1997 Clin. Cancer Res. 56:3689-3694
	BC	Roth and Cristiano, "Gene Therapy for Cancer: What Have We Done and Where Are We Going?", 1997 J. Natl. Canc. Inst. 89(1):21-39
	BD	Rowinsky, E.K., et al., "Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administred as a Ninety-Minute Infusion Every 3 Weeks", 1994 Cancer Res. 54:427-436
	BE	Satoh, T., et al., "Metabolic Activation of CPT-11, 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a Novel Antitumor Agent, by Carboxylesterase" 1994 Biol. Pharm. Bull. 17:662-664
	BF	Senter, P.D., et al., "The Role of Rat Serum Carboxylesterase in the Activation of Paclitaxel and Camptothecin Prodrugs", 1996 Cancer Res. 56:1471-1474
	BG	Tanizawa, A., et al., "Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials", 1994 J. Natl. Cancer Inst. 86:836-842
	BH	Tsuji, T., et al., "CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties", 1991 J. Pharmacobio. Dynamics 14:341-349
	BI	Yamada, H., et al., "AMPLIFICATIONS OF BOTH c-Ki-ras WITH A POINT MUTATION AND c-myc IN A PRIMARY PANCREATIC CANCER AND ITS METASTATIC TUMORS IN LYMPH NODES", 1986 Jpn. J. Cancer Res. 77:370-375
✓	BJ	Yang, N.S., "Gene Transfer into Mammalian Somatic Cells In Vivo", 1992 Crit. Rev. Biotechnol. 12:335-356

EXAMINER

DATE CONSIDERED

1/17/02